Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia

Figures & data

Table 1 Summary of references by topic and study description

Outcome category	Study	Study description
Medication adherence	Lindenmayer et al^Citation8	Randomized, double-blind
	Morken et al^Citation10	Open-label
	Perkins et al^Citation11	Randomized, double-blind
	Verdoux et al^Citation12	Observational
	Coldham et al^Citation14	Observational
	Cooper et al^Citation16	Population-based
	Staring et al^Citation20	Randomized
	Novick et al^Citation21	Observational
	Ritchie et al^Citation22	Open-label
	Ascher-Svanum et al^Citation23	Prospective, observational
	McCabe et al^Citation70	Observational
Clinical	Crumlish et al^Citation4	Prospective, longitudinal
	Leucht et al^Citation5	Meta-analysis
	Robinson et al^Citation7	Prospective, open-label
	Lieberman et al^Citation13	Randomized, double-blind
	Tiihonen et al^Citation30	Prospective cohort
	Brnabic et al^Citation32	Observational
	Shi et al^Citation33	Observational
	Olivares et al^Citation27	Longitudinal, observational
	Zhu et al^Citation34	Prospective, open-label
	Rosenheck et al^Citation35	Randomized, open-label
	Haddad et al^Citation36	Systematic review
	Fusar-Poli et al^Citation37	Meta-analysis of RCTs
	Kishimoto et al^Citation38	Meta-analysis of RCTs
	Andreasen et al^Citation42	Longitudinal, observational
	Kelin et al^Citation67	Prospective, observational
	Kelin et al^Citation68	Prospective, observational
Early treatment with LAIs	Bartzokis et al^Citation40	Randomized, open-label
	Bartzokis^Citation41	Randomized, open-label
	Andreasen et al^Citation42	Longitudinal, observational
	Taylor and Ng^Citation43	Systematic review
	Ascher-Svanum et al^Citation44	Randomized, double-blind, prospective cohort
Health care resource utilization	Olivares et al^Citation26	Longitudinal, observational
	Offord et al^Citation28	Claims database
	Peng et al^Citation29	Claims database
	Ren et al^Citation31	Open-label
	Crivera et al^Citation45	Observational
	Taylor et al^Citation46	Medical record review
	Lin et al^Citation47	Claims database
	Bera et al^Citation48	Claims database
Impact on quality of life	Puschner et al^Citation69	Randomized, open-label
	Lloyd et al^Citation50	Observational
	De Marinis et al^Citation51	Open-label
	Macfadden et al^Citation52	Longitudinal, observational
	Witte et al^Citation53	Randomized, double-blind, prospective cohort
	Lambert et al^Citation54	Open-label
	Llorca et al^Citation55	Open-label
	Furiak et al^Citation49	Economic model
	Osborne et al^Citation56	Time trade-off study
Attitudes and perceptions toward LAIs	Mohamed et al^Citation71	Randomized, open-label
	Dibonaventura et al^Citation72	Nationwide survey
	Patel et al^Citation73	Cross-sectional survey
	Patel et al^Citation57	Survey
	West et al^Citation58	Survey
	Hamann et al^Citation59	Survey
	Heres et al^Citation60	Survey
	Jaeger and Rossler^Citation61	Survey
	Heres et al^Citation62	Survey
	Waddell and Taylor^Citation63	Systematic review
	Heres et al^Citation64	Survey
	Walburn et al^Citation65	Systematic review
	Velligan et al^Citation81	Systematic review

Abbreviations: RCTs, randomized controlled trials; LAIs, long-acting injectables.

LindenmayerJPLiu-SeifertHKulkarniPMMedication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJ Clin Psychiatry200970799099619497244

 PubMed Web of Science ®Google Scholar

MorkenGWidenJHGraweRWNon-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry200883218447935

 PubMed Web of Science ®Google Scholar

PerkinsDOGuHWeidenPJMcEvoyJPHamerRMLiebermanJAPredictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter studyJ Clin Psychiatry200869110611318312044

 PubMed Web of Science ®Google Scholar

VerdouxHLengronneJLiraudFMedication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjectsActa Psychiatr Scand2000102320321011008856

 PubMed Web of Science ®Google Scholar

ColdhamELAddingtonJAddingtonDMedication adherence of individuals with a first episode of psychosisActa Psychiatr Scand2002106428629012225495

 PubMed Web of Science ®Google Scholar

CooperDMoisanJGrégoireJPAdherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophreniaJ Clin Psychiatry200768681882517592904

 PubMed Web of Science ®Google Scholar

StaringABVan der GaagMKoopmansGTTreatment adherence therapy in people with psychotic disorders: randomised controlled trialBr J Psychiatry2010197644845521119150

 PubMed Web of Science ®Google Scholar

NovickDHaroJMSuarezDPerezVDittmannRWHaddadPMPredictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophreniaPsychiatry Res201017620310911320185182

 PubMed Web of Science ®Google Scholar

RitchieCWHarriganSMastwykMMacfarlaneSCheesmanNAmesDPredictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years durationInt J Geriatr Psychiatry201025441141819946860

 PubMed Web of Science ®Google Scholar

Ascher-SvanumHFariesDEZhuBErnstFRSwartzMSSwansonJWMedication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careJ Clin Psychiatry200667345346016649833

 PubMed Web of Science ®Google Scholar

McCabeRBullenkampJHanssonLThe therapeutic relationship and adherence to antipsychotic medication in schizophreniaPLoS One201274e3608022558336

 PubMed Web of Science ®Google Scholar

CrumlishNWhittyPClarkeMBeyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosisBr J Psychiatry20091941182419118320

 PubMed Web of Science ®Google Scholar

LeuchtSTardyMKomossaKAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet201237998312063207122560607

 PubMed Web of Science ®Google Scholar

RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501

 PubMed Web of Science ®Google Scholar

LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203

 PubMed Web of Science ®Google Scholar

TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741

 PubMed Web of Science ®Google Scholar

BrnabicAJKelinKAscher-SvanumHMontgomeryWKadziolaZKaragianisJMedication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational studyInt J Clin Pract201165994595321849009

 PubMed Web of Science ®Google Scholar

ShiLAscher-SvanumHZhuBFariesDMontgomeryWMarderSRCharacteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophreniaPsychiatr Serv200758448248817412849

 PubMed Web of Science ®Google Scholar

OlivaresJMRodriguez-MoralesADielsJPoveyMJacobsAZhaoZLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)Eur Psychiatry200924528729619195847

 PubMed Web of Science ®Google Scholar

ZhuBAscher-SvanumHShiLFariesDMontgomeryWMarderSRTime to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophreniaPsychiatr Serv200859331531718308914

 PubMed Web of Science ®Google Scholar

RosenheckRAKrystalJHLewRLong-acting risperidone and oral antipsychotics in unstable schizophreniaN Engl J Med2011364984285121366475

 PubMed Web of Science ®Google Scholar

HaddadPMTaylorMNiazOSFirst-generation antipsychotic long-acting injections v oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studiesBr J Psychiatry Suppl200952S20S2819880913

 PubMedGoogle Scholar

Fusar-PoliPKemptonMJRosenheckRAEfficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trialsInt Clin Psychopharmacol2013282576623165366

 PubMed Web of Science ®Google Scholar

KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophr Bull Epub122013

 Web of Science ®Google Scholar

AndreasenNCLiuDZiebellSVoraAHoBCRelapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI studyAm J Psychiatry2013170660961523558429

 PubMed Web of Science ®Google Scholar

KelinKBrnabicAJNewtonRBaseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherencePatient Prefer Adherence2010430131120859457

 PubMed Web of Science ®Google Scholar

KelinKLambertTJrBrnabicAJTreatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherencePatient Prefer Adherence2011521322221660103

 PubMed Web of Science ®Google Scholar

BartzokisGLuPHRavenEPImpact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophreniaSchizophr Res20121401–312212822809684

 PubMed Web of Science ®Google Scholar

BartzokisGSchizophrenia: breakdown in the well-regulated lifelong process of brain development and maturationNeuropsychopharmacology200227467268312377404

 PubMed Web of Science ®Google Scholar

TaylorMNgKYShould long-acting (depot) antipsychotics be used in early schizophrenia? A systematic reviewAust N Z J Psychiatry201347762463023209308

 PubMed Web of Science ®Google Scholar

Ascher-SvanumHZhaoFDetkeHCEarly response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophreniaBMC Psychiatry20111115221943257

 PubMed Web of Science ®Google Scholar

OlivaresJMRodriguez-MartinezABurónJAAlonso-EscolanoDRodriguez-MoralesACost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in SpainAppl Health Econ Health Policy200861415318774869

 PubMedGoogle Scholar

OffordSWongBMirskiDBakerRALinJHealthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oralJ Med Econ201316223123923163287

 PubMedGoogle Scholar

PengXAscher-SvanumHFariesDConleyRRSchuhKJDecline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophreniaClinicoecon Outcomes Res2011391421935327

 PubMedGoogle Scholar

RenXSCriveraCSikiricaMDiraniRQianSKazisLEEvaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the Veterans Health AdministrationJ Clin Pharm Ther201136338338921062329

 PubMed Web of Science ®Google Scholar

CriveraCDeSouzaCKozmaCMDiraniRDMaoLMacfaddenWResource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)BMC Psychiatry20111116821999370

 PubMed Web of Science ®Google Scholar

TaylorMCurrieALloydKPriceMPeperellKImpact of risperidone long acting injection on resource utilization in psychiatric secondary careJ Psychopharmacol200822212813118308820

 PubMed Web of Science ®Google Scholar

LinJWongBOffordSMirskiDHealthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophreniaJ Behav Health Serv Res201340335536623579871

 PubMed Web of Science ®Google Scholar

BeraROffordSZubekDImpact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychoticsJ Med Econ201316452252823360177

 PubMedGoogle Scholar

PuschnerBAngermeyerMCLeeseMCourse of adherence to medication and quality of life in people with schizophreniaPsychiatry Res2009165322423319155070

 PubMed Web of Science ®Google Scholar

LloydKLatifMASimpsonSShresthaKLSwitching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcomeHum Psychopharmacol201025324325220373476

 PubMed Web of Science ®Google Scholar

De MarinisTSaleemPTGluePSwitching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophreniaPharmacopsychiatry200740625726318030649

 PubMed Web of Science ®Google Scholar

MacfaddenWDeSouzaCCriveraCAssessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsBMC Psychiatry20111116721999346

 PubMed Web of Science ®Google Scholar

WitteMMCaseMGSchuhKJAscher-SvanumHEffects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophreniaCurr Med Res Opin201228331532322236137

 PubMed Web of Science ®Google Scholar

LambertMDe MarinisTPfeilJNaberDSchreinerAEstablishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatmentEur Psychiatry201025422022919926263

 PubMed Web of Science ®Google Scholar

LlorcaPMBouhoursPMoreau-MalletVImproved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidoneEncephale200834217017818597725

 PubMed Web of Science ®Google Scholar

FuriakNMGahnJCKleinRWCamperSBSummersKHEstimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision modelAnn Gen Psychiatry20121112923157721

 PubMed Web of Science ®Google Scholar

OsborneRHDaltonAHertelJSchroverRSmithDKHealth-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off studyHealth Qual Life Outcomes2012103522472127

 PubMed Web of Science ®Google Scholar

MohamedSRosenheckRMcEvoyJSwartzMStroupSLiebermanJACross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophreniaSchizophr Bull200935233634618586692

 PubMed Web of Science ®Google Scholar

DibonaventuraMGabrielSDupclayLGuptaSKimEA patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophreniaBMC Psychiatry2012122022433036

 PubMed Web of Science ®Google Scholar

PatelMXde ZoysaNBernadtMDavidASA cross-sectional study of patients’ perspectives on adherence to antipsychotic medication: depot versus oralJ Clin Psychiatry200869101548155619192437

 PubMed Web of Science ®Google Scholar

PatelMXHaddadPMChaudhryIBMcLoughlinSHusainNDavidASPsychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 yearsJ Psychopharmacol201024101473148219477883

 PubMed Web of Science ®Google Scholar

WestJCMarcusSCWilkJCountisLMRegierDAOlfsonMUse of depot antipsychotic medications for medication nonadherence in schizophreniaSchizophr Bull2008345995100118093962

 PubMed Web of Science ®Google Scholar

HamannJMendelRHeresSLeuchtSKisslingWHow much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?Eur Neuropsychopharmacol201020427627920133108

 PubMed Web of Science ®Google Scholar

HeresSHamannJKisslingWLeuchtSAttitudes of psychiatrists toward antipsychotic depot medicationJ Clin Psychiatry200667121948195317194274

 PubMed Web of Science ®Google Scholar

JaegerMRosslerWAttitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatristsPsychiatry Res20101751–2586220004980

 PubMed Web of Science ®Google Scholar

HeresSReichhartTHamannJMendelRLeuchtSKisslingWPsychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophreniaEur Psychiatry201126529730120570493

 PubMed Web of Science ®Google Scholar

WaddellLTaylorMAttitudes of patients and mental health staff to antipsychotic long-acting injections: systematic reviewBr J Psychiatry Suppl200952S43S5019880916

 PubMedGoogle Scholar

HeresSSchmitzFSLeuchtSPajonkFGThe attitude of patients towards antipsychotic depot treatmentInt Clin Psychopharmacol200722527528217690596

 PubMed Web of Science ®Google Scholar

WalburnJGrayRGournayKQuraishiSDavidASSystematic review of patient and nurse attitudes to depot antipsychotic medicationBr J Psychiatry200117930030711581109

 PubMed Web of Science ®Google Scholar

VelliganDIMedellinEDraperMBarriers to, and strategies for, starting a long acting injection clinic in a community mental health centerCommunity Ment Health J201147665465921253830

 PubMed Web of Science ®Google Scholar